SCHEMBL7928161

SCHEMBL7928161

C=CC[C@@H](O)COCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.52
HTT P42858 1/20 0.50
LPAR5 Q9H1C0 1/20 0.44
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
PLA2G2C Q5R387 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 2/20 0.39
SPHK1 Q9NYA1 1/20 0.39
HPGD P15428 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CASR P41180 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841203 1.00 USP2 (0.52) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL13421955 1.00 USP2 (0.52) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL8303499 0.93 USP2 (0.62) USP2HTTLPAR5CYP1A2CYP3A4
SCHEMBL11513826 0.90 HSD17B10 (0.52) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL13103508 0.83 USP2 (0.44) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL13841296 0.83 TSHR (0.42) USP2HTTLPAR5CYP1A2CYP3A4
SCHEMBL17889168 0.83 CA1 (0.53) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL12204744 0.81 USP2 (0.49) USP2HTTLPAR5HSD17B10CYP1A2
SCHEMBL14440651 0.81 PLA2G2C (0.51) USP2HTTLPAR5HSD17B10CYP1A2
Dibuprol SCHEMBL1816462 0.81 USP2 (0.65) USP2HTTLPAR5HSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362248-A1 C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-12-21 US disclosed
WO-2016085780-A1 C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-06-02 WO disclosed
US-8198269-B2 Fused aminodihydrothiazine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-06-12 US disclosed
US-20110207723-A1 NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-08-25 US disclosed
US-20100093999-A1 NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-15 US disclosed
WO-2010038686-A1 NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093999-A1 NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE BACE1, BACE2, APP USP2 2255/4885HTT 267/4885LPAR5 1966/4885
US-20110207723-A1 NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE BACE1, APP, BACE2 USP2 3516/4885HTT 231/4885LPAR5 1666/4885
US-20170362248-A1 C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, APP, PSEN1 USP2 3059/4885HTT 1088/4885LPAR5 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.